This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): BT-063
Description: BT-063 is being developed for the lead indication of systemic lupus erythematosus (SLE). The monoclonal antibody specifically neutralises a cell growth factor which plays an important role in the development and symptoms of the disease.
Pink Sheet Weekly Trademark Review July 28, 2015
Pink Sheet Weekly Trademark Review May 12, 2015
Pink Sheet Weekly Trademark Review July 22, 2014
Additional information available to subscribers only: